Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

AstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary albumin-to-creatinine ratio (UACR) in patients with albuminuria and both chronic kidney ...

ALEXION PHARMACEUTICALS, INC.'s most active month to dispose stocks was the month of June. 2020 saw ALEXION PHARMACEUTICALS, INC. paying a total of $0.00 for 1,109,910 shares, ...

Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion.

Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) price-to-earnings (or "P/E") ratio of 56.5x might make it look like a strong sell right now compared to the market in the United States, where around ...

Alexion Pharmaceuticals is being acquired by AstraZeneca, company officials announced on Saturday, Dec. 12, 2020. The deal is worth $39 billion, the Associated Press reported.

AstraZeneca on Saturday said it would acquire Alexion Pharmaceuticals for $39 billion. "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to ...

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) just released its quarterly report and things are looking bullish. Alexion Pharmaceuticals delivered a significant beat to revenue and earnings per ...